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Abstract: Extracorporeal membrane oxygenation (ECMO) 
for respiratory failure was reviewed. ECMO progressed 
from laboratory research to initial clinical trials in 1972. 
Following a decade of clinical research, ECMO is now 
standard treatment for neonatal respiratory failure refrac- 
tory to conventional pulmonary support techniques 
worldwide. The application of neonatal ECMO has been 
extended with improved outcome to premature and low 
birth weight infants as well as older children and adults. 
Extracorporeal membrane oxygenation (ECMO) 
refers to the use of prolonged extracorporeal circu- 
lation for temporary support of the failing heart or 
lungs. ‘The first successful ECMO support case was 
done by Hill et  al. in 1971. Reports of several other 
successful cases soon followed. In 1974, the Lung 
Division of the National Heart and Lung Institute 
proposed a multicenter prospective randomized 
study of ECMO in adult respiratory failure. This 
study began in 1975. In that year a meeting on pro- 
longed extracorporeal support was held outside of 
Copenhagen. The plans for the NIH-ECMO study 
were reported and reviewed at that meeting. The 
firbt successful newborn infant with ECMO was 
also reported on at the meeting. 
NEONATAL ECMO 
Bartlett, Gazzaniga, and his colleagues at the 
University of California-Irvine treated the first suc- 
cessful neonatal ECMO patient in 1975. This was 
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As of July 1994, 9,258 neonates, 754 pediatric, and 130 
adult patients with respiratory failure treated with ECMO 
were entered in the registry of the Extracorporeal Life 
Support Organization (ELSO). Overall survival rates 
were 81% in neonates, 49% in pediatric, and 38% in adult 
patients. Recently the adult and pediatric populations 
treated with ECMO have increased rapidly, and the out- 
come has improved significantly. Key Words: Extracor- 
poreal membrane oxygenation-Respiratory failure. 
soon followed by other successful neonatal cases. 
The technique for newborn infants was fairly stan- 
dardized including the ECMO technique and recog- 
nition of persistent pulmonary hypertension as the 
primary underlying pathophysiology. In 1979, the 
first neonatal ECMO seminar was held at  the Uni- 
versity of California-Irvine, demonstrating the cir- 
cuit, technology, and concept of the ECMO team 
and specialists. In 1980, the neonatal ECMO project 
moved to the University of Michigan. By the end of 
1986,715 newborn cases had been treated in 18 cen- 
ters with excellent survival results reported from 
each center. The Michigan group carried out a pro- 
spective randomized study in newborn infants be- 
tween 1982 and 1984, using a statistical technique 
called randomized play-the-winner, in which as- 
signment to  one treatment or the other is random- 
ized but influenced by all previous patients in the 
study. Statistical significance is reached when there 
is a significantly larger group of patients in one arm 
of the study compared with the other (I). O’Rouke 
et al. carried out a prospective randomized study 
comparing ECMO and conventional medical ther- 
apy in neonates with persistent pulmonary hyper- 
tension of the newborn between 1982 and 1983 (2).  
They proved that the results with ECMO were bet- 
ter than conventional therapy. 
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ECMO became standard care for severe neonatal 
respiratory failure in 1986-87. In 1988, venovenous 
bypass using a double lumen catheter became avail- 
able with excellent outcome (3). The current tech- 
nique of ECMO includes venoarterial access via the 
right internal jugular vein and right carotid artery, 
heparin titration based upon whole blood activated 
clotting times (ACT), and "lung rest" at low venti- 
lator settings (4). The extracorporeal circuit con- 
sists of a collapsible bladder in the venous line (pro- 
viding control of a roller pump) and a solid silicone 
rubber membrane oxygenator (Avecor, Inc. Minne- 
apolis, MN). Blood is circulated through a heat ex- 
changer and then returned to the patient. Sweep gas 
flow to the oxygenator typically consists of a mix- 
ture of 100% oxygen, carbogen (95% oxygen and 
5% carbon dioxide) to maintain Paco, between 30 
and 40 mm Hg. Anticoagulation is achieved by con- 
stant heparin infusion, maintaining the ACT be- 
tween 180 and 200 s. Platelet counts are maintained 
above 100,000/mm3. The hematocrit values are kept 
above 40%. Initial bypass flow is about 80-100 ml/ 
kg/min in the venoarterial bypass mode and 100-120 
ml/kg/min in the venovenous mode. Patients are 
weaned according to SVo, and Pao, values. On ini- 
tiation of bypass, ventilator settings are decreased 
to an inspired oxygen concentration of 30%, peak 
airway pressure <30 cm of H,O, PEEP usually 
maintained at 5 cm of H,O, and a respiratory rate of 
10 beatslmin. 
The active groups formed a study group in 1989 
called the Extracorporeal Life Support Organiza- 
tion (ELSO). ELSO maintains the registry, con- 
ducts courses, holds an annual meeting to share ex- 
perience, and represents the membership to the 
community. Schumacher et al. reported a cost ef- 
fectiveness study demonstrating that the early use 
of ECMO does not increase hospital cost or utiliza- 
tion and suggests a lower morbidity rate (5) .  The 
application of ECMO is now being extended to pre- 
mature and low birth weight infants (6). A follow-up 
study reported that 80% of survivors were healthy 
children. The remaining 20% have some degree of 
pulmonary or neurologic impairment. Death or dis- 
ability is caused by perinatal neurologic injury or 
pulmonary hypoplasia (7). In 1994, there were 
nearly 100 ECMO centers throughout the world. 
Over 9,000 newborn infants have been treated with 
ECMO with an 81% overall survival rate (Table 1)  
(8). Bleeding was the most frequent complication. 
ECMO is now standard treatment for severe neo- 
natal respiratory failure. The availability of ECMO 
has made the evaluation of other innovative meth- 
ods of treatment, such as late elective repair 
TABLE 1. Percent survival by primary diagnosis for  
neonatal ECMO 
University of International 
Primary Michigan" 
diagnosis (n = 470) (n = 9,258) 
registry 
MAS 97% (165/170) 
RDSIHMD 88% (80/91) 
Pneumonidsepsis 83% (65/78) 
CDH 66% (45/68) 
PPHNiPFC 92% (35/38) 
Other 75% (18/24) 
Overall 87% (408/470) 









MAS, meconium aspiration syndrome; RDS, respiratory dis- 
tress syndrome; HMD, hyaline membrane disease; CDH, con- 
genital diaphragmatic hernia; PPHN, persistent pulmonary hy- 
pertension of the newborn; PFC, persistent fetal circulation. 
" Includes initial 45 cases treated at the University of Califor- 
nia-lrvine. Data from the ECMO registry report of the ELSO as 
of July 1994. 
of diaphragmatic hernia, and new pulmonary va- 
sodilators, such as nitric oxide (9) possible. 
PEDIATRIC AND ADULT ECMO 
An NIH-sponsored study of ECMO in adult pa- 
tients was completed in 1979 and reported (10). Al- 
though there were many problems with this study, 
this was the first attempt at a prospective random- 
ized study of the ECLS technique in which the end 
point was death. Some centers had no prior expe- 
rience before their first study patient. Bleeding 
complications were major with average blood loss 
exceeding 2 L/day. Although the purpose of ECMO 
is lung rest, many of the patients remained on high 
ventilator settings under the venoarterial bypass 
mode. The study was planned for 300 patients, but 
it was terminated after 92 patients were entered be- 
cause the survival in both groups was less than 
10%. Autopsy revealed that extensive and irrevers- 
ible pulmonary fibrosis was uniformly formed, in- 
dicating that the major problem was underlying pa- 
renchymal lung disease. As the result of this study, 
clinical research on ECMO in adult patients essen- 
tially stopped in the United States in 1979. Gatti- 
noni and his colleagues in Milan started using a new 
method for extracorporeal life support with the fol- 
lowing hypothesis. First, the purpose of ventilation 
is to excrete carbon dioxide. Oxygenation can be 
achieved by inflation and airway oxygenation 
alone. Second, progressive lung injury in acute re- 
spiratory distress syndrome (ARDS) is caused in 
part by ventilator-induced high pressure or over- 
distension injury of the most normal alveoli. Third, 
if the emphasis should be on carbon dioxide re- 
moval to eliminate the need for high pressure ven- 
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tilation, this could be accomplished with veno- 
venous access using relatively low blood flow and a 
large membrane lung surface area. Fourth, this sys- 
tem would allow for normal pulmonary blood flow, 
even if the lung is severely injured with large 
amounts of transpulmonary shunting. They used 
these principles in venovenous extracorporeal gas 
exchange with low-frequency positive pressure 
ventilation in a variety of adult patients selected by 
the same criteria used for the NIH ECMO study. 
They reported their study with 49% survival in 1986 
(1 I). These results have been corroborated in many 
European centers, and similar results were reported 
by the Kumamoto group in Japan. 
Based on these reports and our experience with 
neonatal ECMO, our institute began to reevaluate 
ECMO in adult patients with cardiopulmonary fail- 
ure in 1988. The ECMO technique for adult patients 
is the same as  neonatal ECMO, including the ven- 
ovenous and venoarterial bypass mode with lung 
rest. Selection criteria for respiratory failure in 
adults with 90% or greater mortality risk includes 
transpulmonary shunt greater than 30%, static com- 
pliance lower than 0.5 ml/cm of H,O/kg, and a dif- 
fusely abnormal chest roentgenogram in four quad- 
rants despite optimal conventional therapy (12). 
Bleeding was the most frequent complication. lndi- 
cators of irreversibility of lung injury in these pa- 
tients were elevated pulmonary artery pressures 
(75% or greater of systemic pressure), decreased 
aeration and lung compliance, and a diminution of 
transpulmonary gas exchange. Patients with more 
than 5 pre-ECMO ventilation days had a signifi- 
cantly higher mortality risk compared with those 
ventilated for less than 5 days. The elevated pulmo- 
nary artery pressure/systemic pressure ratio, trans- 
forming growth factor p (TGF-P) activity in the 
Broncho alveolar lovage fluid (BALF), and mea- 
surement of oxygen transfer across the native lung 
during ECMO may be good early predictors for the 
TABLE 2. Percent survival by primary diagnosis for  
pediatric ECMO 
University of International 
Primary Michigan registry 























46% ( I62/350) 
49% (3731754) 
ARDS, adult respiratory distress syndrome. Data from ECMO 
registry report of the ELSO. 
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TABLE 3. Percent survival by primary diagnosis f o r  
adult ECMO 
~ 
University of Michigan 
Primary diagnosis (n = 48) 
Bacterial pneumonia 14% (117) 
Viral pneumonia 88% (7/8) 
Aspiration 67% (2/3) 
ARDS 70% (16/23) 
Overall 63% (30/48) 
Other 57% (4/7) 
ARDS, adult respiratory distress syndrome. Data from ECMO 
registry report of the ELSO. 
reversibility of lung injury. As of July 1994, 48 pa- 
tients with severe respiratory failure have been 
treated with ECMO with 30 survivors (63%) at the 
University of Michigan (Table 2) (8). The difference 
in the results of modern ECMO and those of the 
1970s, when the NIH-ECMO study was performed, 
may in part be due to better case selection, veno- 
venous perfusion, and improvement in the technol- 
ogy of long-term perfusion (12). Advances in critical 
care techniques today may improve the survival 
from respiratory failure. 
For older children (between 1 month and 18 years 
of age) who have failed conventional mechanical 
ventilation, ECMO has also been proposed and uti- 
lized as a rescue therapy. As of July 1994, 754 pe- 
diatric cases have been treated with ECMO therapy 
with an overall survival rate of 49% (Table 3) (8). 
Our institute has experienced 62 cases with an over- 
all survival rate of 66% (8). In the near future, rou- 
tine use of heparin-coated equipment will reduce 
the complication associated with systemic heparin- 
ization and blood material interaction. 
CONCLUSION 
ECMO has become standard treatment for severe 
neonatal respiratory failure in our institute and 
worldwide. The application of ECMO is now being 
extended to premature and low birth weight infants 
as well as older children and adults. The outcome of 
ECMO for adult and pediatric patients in our insti- 
tute showed that it was a reasonable therapy for 
patients with severe respiratory failure who failed 
to recover with conventional medical therapy. 
Technical advances will lead to a better outcome 
with much easier and safer use of ECMO in the 
future. 
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